The main objective of this trial is to investigate the relative bioavailability of BI 425809 given alone (Reference) compared to a combined administration with the moderate CYP3A4 inducer bosentan (Test) following repeated oral administration.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Time frame: On Day 10 of period 1 and on Day 14 of period 2.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Time frame: On Day 10 of period 1 and on Day 14 of period 2.
Minimum concentration of the analyte in plasma at steady state within a uniform dosing interval τ (Cmin,ss)
Time frame: On Day 10 of period 1 and on Day 14 of period 2.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.